Bevacizumab Injection

Bevacizumab Injection is a finished sterile intravenous formulation manufactured by Hualan Biological Engineering Inc., combining bevacizumab with alginate dihydrate, sodium dihydrogen phosphate monohydrate, disodium hydrogen phosphate dodecahydrate, polysorbate 20 and water for injection into a colorless to light brown, pH 5.9-6.3 solution. Per the supplier, it is indicated for advanced or metastatic non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular cancer, and epithelial ovarian, fallopian tube, primary peritoneal and cervical cancers; samples are available, and it is distributed across Asia, North America, Central/South America, Western and Eastern Europe, Australasia, the Middle East and Africa.